Biosimilars and biopharmaceuticals: What the nephrologists need to know - A position paper by the ERA-EDTA Council

Nephrology Dialysis Transplantation

Volumn 23, Issue 12, 2008, Pages 3731-3737

  Covic, Adrian ^a   Cannata Andia, Jorge ^b   Cancarini, Giovanni ^c   Coppo, Rosanna ^d   Frazão, João M ^e   Goldsmith, David ^f   Ronco, Pierre ^g   Spasovski, Goce B ^h   Stenvinkel, Peter ⁱ   Utas, Cengiz ^j   Wiecek, Andrzej ^k   Zoccali, Carmine ^l   London, Gerard ^m  

^a C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^b UNIVERSITY OF OVIEDO   (Spain)

^c Nephrology Institute   (Italy)

^d REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g INSERM   (France)

^h SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^k MEDICAL UNIVERSITY OF SILESIA   (Poland)

^l BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^m CENTRE HOSPITALIER   (France)

more..

Author keywords

Biopharmaceuticals; Biosimilars; ERA EDTA position paper; Pharmacovigilance

Indexed keywords

BIOLOGICAL PRODUCT; CERIVASTATIN; GENERIC DRUG; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT PROTEIN; ROFECOXIB;

ANEMIA; AREA UNDER THE CURVE; DEAMINATION; DRUG CONTAMINATION; DRUG HALF LIFE; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EUROPE; GOOD MANUFACTURING PRACTICE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NOTE; OXIDATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN GLYCOSYLATION; STANDARDIZATION;

EID: 56749163625     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn519     Document Type: Note

References (42)

1. EMEA Committee for Medicinal Products for Human Use. Silapo European Public Assessment Report, London, 2007. Available at: http://www.emea.eu.int
2. EMEA Committee for Medicinal Products for Human Use. Questions and answers on recommendation for refusal of marketing application for Alpheon: International Non-proprietary Name (INN): interferon alfa-2a. London, 2006. Available at: http://www.emea.eu.int
3. PhRMA (Pharmaceutical Research and Manufacturers of America. Medicines in development: Biotechnology, 2006 report. Available at: http://www.phrma.org/ files/Biotech%202006.pdf
4. Kerpel-Fronius S. Clinical pharmacologic principles of the development and application of follow-on biological medicinal products [Article in Hungarian]. Orv Hetil 2007; 148: 915-921
5. Locatelli F, Roger S. Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant 2006; 21(Suppl 5): v13-v16
6. Furberg CD, Herrington DM, Psaty BM. Are drugs within a class interchangeable? Lancet 1999; 354: 1202-1204
7. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med 2000; 132: 715-772
8. Song F, Altman DG, Glenny AM et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326: 472
9. McAlister FA, Laupacis A, Wells GA et al. Users' Guides to the Medical Literature: XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999; 282: 1371-1377
10. Chow K, Tong HH, Lum S et al. Engineering of pharmaceutical materials: An industrial perspective. J Pharm Sci 2007; 97: 2855-2877
11. European Commission: Enterprise and Industry Directorate General. EudraLex: The Rules Governing Medicinal Products in the European Union. Volume 4 - Good Manufacturing Practices: Medicinal Products for Human and Veterinary Use. Available at: http://ec.europa.eu/enterprise/ pharmaceuticals/eudralex/homev4.htm
12. EMEA. Note for guidance on good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00). London, 2000. Available at:http://www.emea.europa.eu/pdfs/human/ich/410600en.pdf
13. MHRA. Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2007. London, Pharmaceutical Press, 2007
14. Yu LX. Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res 2008; 25: 781-791
15. Yang W, Israni RK, Brunelli SM et al. Hemoglobin variability and mortality in ESRD. J Am Soc Nephrol 2007; 18: 3164-3170
16. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease, 2006. Available at: http://www.kidney.org/professionals/KDOQI/guidelines_anemia/index.htm
17. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
18. Kessler M, Goldsmith D, Schellekens H. Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant 2006; 21(Suppl 5): v9-v12
19. Casadevall N, Nataf J, Viron B et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
20. Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans - clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3: 349-360
21. Cleland JL, Powell MF, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993; 10: 307-377
22. Hoglund M. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) - what is the difference? Med Oncol 1998; 15: 229-233
23. Dove A. Uncorking the biomanufacturing bottleneck. Nat Biotechnol 2002; 20: 777-779
24. Restelli V, Wang MD, Huzel N et al. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol Bioeng 2006; 94: 481-494
25. Misaizu T, Matsuki S, Strickland TW et al. Role of antennary structure of N-linked sugar chains in renal handling of recombinant human erythropoietin. Blood 1995; 86: 4097-4104
26. Sharma B. Immunogenicity of therapeutic proteins: Part 2. Impact of container closures. Biotechnol Adv 2007a; 25: 318-324
27. Sharma B. Immunogenicity of therapeutic proteins: Part 1. Impact of product handling. Biotechnol Adv 2007b; 25: 310-317
28. Li S, Schöneich C, Borchardt RT. Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 1995; 48: 490-500
29. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24: 1720-1740
30. Hermeling S, Crommelin DJ, Schellekens H et al. Structure-immunogenicity relationships of therapeutic proteins. Pharm Res 2004; 21: 897-903
31. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8: E501-E507
32. Schellekens H. The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol 2008; 3: 174-178
33. Schellekens H. Erythropoietic proteins and antibody-mediated pure red cell aplasia: a potential role for micelles. Nephrol Dial Transplant 2004; 19: 2422
34. Jenkins N. Modifications of therapeutic proteins: challenges and prospects. Cytotechnology 2007; 53: 121-125
35. Boylan JC, Swarbrick J. Encyclopedia of Pharmaceutical Technology, 2nd edn. New York: Marcel Dekker, Inc., 2002: 214
36. EMEA Committee for Medicinal Products for Human Use. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. London, 2006 Available at: http://www.emea.eu.int/
37. EMEA Committee for Medicinal Products for Human Use. Guidelines on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. London, 2006. Available at: http://www.emea.eu.int/
38. Mellstedt H, Niederwasser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19: 411-419
39. Locatelli F, Goldsmith D. Biosimilars: uncharted territory. J Nephrol 2007; 20: 265-267
40. European Biopharmaceutical Enterprises. EBE-EFPIA Position paper: inapplicability of automatic substitution rules to biotechnology products, including biosimilar medicinal products: recommendation for addressing unique safety concerns. 31 July 2006. Available at: http://www.ebe-biopharma.org
41. European Biopharmaceutical Enterprises. EBE-EFPIA Position paper: Naming of biosimilar medicinal products: options for addressing unique safety concerns. 7 July 2006. Available at: http://www.ebebiopharma.org
42. http://www.who.int/medicines/services/inn/ 46thINNConsultation_ExecSummary.pdf